Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial t...

Descripción completa

Detalles Bibliográficos
Autores principales: Simões, Belinda Pinto, Braga Junior, José Wilson Ramos, Rego, Maria Aparecida do Carmo, de Souza, Cármino Antônio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Hematologia e Hemoterapia 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521438/
https://www.ncbi.nlm.nih.gov/pubmed/23284246
http://dx.doi.org/10.5581/1516-8484.20110017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521438/
https://www.ncbi.nlm.nih.gov/pubmed/23284246
http://dx.doi.org/10.5581/1516-8484.20110017

Ejemplares similares